2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA
Senti Holdings Issues $10 Million in Senior Secured Convertible Notes
Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
Senti Biosciences Enters $40 Million Securities Purchase Agreement
Other Events
Financial Results, Press Release
Lease Amendment - Senti Biosciences Reduces Leased Premises Size
Investor Presentation
Senti Bio Q3 2025 Financial Results and Next Clinical Data for SENTI-202 Study
Q1
Amended Annual Report
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Notice of Suspension of Duty to File Reports
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
S-8 POS
Post-Effective Amendment to Registration Statement
Current Report for Successor Issuer